Navigation Links
Brain tumors found to have a 2-tier system
Date:8/23/2011

Ependymomas are the second most frequent type of malignant brain tumor in children. Ependymoma develops from precursor cells of the tissue that lines the hollow cavities of the brain. Therapy results of ependymoma vary immensely: While in some patients tumor growth comes to a standstill after surgery and radiotherapy, in other children the disease rapidly takes a severe course. In about half of those affected the tumor continues to grow and the patients often succumb to the disease.

It is the patients with a severe course, in particular, who urgently need better therapies. To this end, we need to understand what makes ependymomas so different in their characteristics," says pediatrician and molecular geneticist Dr. Stefan Pfister, who is a researcher at DKFZ and Heidelberg University Hospitals. Jointly with his colleague, Dr. Hendrik Witt, Pfister and researchers from Canada, the U.S.A., Russia, Poland and Italy are now publishing the results of the largest ever molecular-genetic study of ependymomas of the cerebellum. This is where this type of tumor is most frequently located in children, while in adults ependymoma usually arises in the cerebrum or in the spinal cord.

In 583 tissue samples of ependymomas of the cerebellum, the investigators studied the activity of individual genes and searched the genetic material for losses or gains of whole DNA segments. Two groups of these tumors were first analyzed independently and the results obtained were subsequently validated based on the tissue samples of a third group. In this way, the investigators obtained particularly valuable results.

The large-scale study has yielded clear results: Based on anomalies of their genetic material, ependymomas of the cerebellum can be classified in two distinct subgroups which also differ clinically. Group A ependymomas take an unfavorable course; such tumors often recur after initial surgery and they frequently metastasize, which ultimately leads to the death of many patients. Group A tumors have relatively few losses or gains of gene segments; however, very many genes that play a role in key cancer signaling pathways are activated.

By contrast, tumors of group B have a favorable prognosis, even though the genome of these cancer cells is highly unstable. Typical characteristics are gains of large segments of chromosomes 9, 15, 18 as well as losses of chromosomes 6 and 22.

"The genetic differences between these two types are so marked that we have to speak of two different diseases that may even arise from different original cells," says Stefan Pfister. The Heidelberg researchers will now take a closer look, in particular, at group A ependymomas in order to find out which of the genetic alterations is what is called the driver mutation, i.e. the mutation that causes carcinogenesis. In this way, they hope to identify potential targets for better drugs to specifically fight the more aggressive group A ependymomas. For several signaling pathways that are hyperactive in group A tumors, targeted drugs have already been developed and are currently being tested for other types of cancer in clinical trials. It is possible that some of these substances may be a treatment option for ependymoma as well.

But patients will also benefit from the results of the genome analysis in the near future: Using simple tests, doctors will be able to assign a case to one of the two subgroups and they will thus be in a better position to decide how intensive treatment must be.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. For depression, relapsers go to the front of the brain
2. Moms Depression Affects Kids Brain Structure, Scans Show
3. New piece to the puzzle of brain function
4. Everyday clairvoyance: How your brain makes near-future predictions
5. Rhode Island Hospital study identifies fish oils impact on cognition and brain structure
6. Profound reorganization in brains of adults who stutter
7. Exercise may help prevent brain damage caused by Alzheimers disease
8. Goldie Hawn to give public lecture on The Brain and the Optimistic Classroom at Aspen Brain Forum
9. Like Those in Humans, Baby Chimps Forebrains Immature
10. Survivors of Brain Hemorrhage May Experience PTSD
11. Deep Brain Stimulation Improves Parkinsons Symptoms Long-Term
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 2017 , ... M&S Technologies, the first name in computerized ... System® 20/20. CE Certification builds upon M&S's long-standing commitment to products and software ... ISO and proven test methods used in the field of Vision Care. Smart ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research study, ... having the skills needed to execute that strategy, and the actual success of ...
(Date:3/27/2017)... ... 27, 2017 , ... According to the American Cancer Society , the ... than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, ... to avoid this latter group, tune in to Lifestyle Magazine on April ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Israel , March 27, 2017 ... oncology and immunology, announced today that AGI-134, an immunotherapy for ... acquisition of Agalimmune Ltd., will be featured at the upcoming ... in Washington, DC to be held ... ...
(Date:3/27/2017)... The staggering cost of cancer treatment means ... to the latest treatment options against cancer. Even among ... have inadequate or no health insurance and are oftentimes ... to modern cancer treatment is almost non-existent for cancer ... The mission statements of pharmaceutical and biotech companies often ...
(Date:3/27/2017)... , March 27, 2017 ... as the NASDAQ Composite closed the trading session up ... and the S&P 500 was down 0.08%. US markets ... sectors finishing the day in green. Pre-market today, Stock-Callers.com ... Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), ...
Breaking Medicine Technology: